沙眼治疗市场 - 按药物类别、给药途径、年龄层、配销通路、全球预测

Trachoma Treatment Market - By Drug Class, Route of Administration, Age-group, Distribution Channel, Global Forecast

出版日期: 2024年04月22日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在四环素和阿奇霉素等治疗药物的进步以及政府的支持措施的推动下，全球沙眼治疗市场从 2024 年到 2032 年将实现 5.9% 的复合年增长率。改良的药物可以提高对抗引起沙眼的细菌感染的功效，而政府的资金和政策则可以促进获得这些治疗的机会。这些共同努力旨在减少全球沙眼的盛行率，强调透过提高该疾病仍然流行的地区的治疗可及性和有效性来扩大市场。

例如，2023 年 12 月，英国皇家热带医学与卫生学会与 Sightsavers 合作，在其期刊《国际健康》上发布了一份新的研究增刊，重点关注传染性眼病沙眼的最新情况。这项进展显示加强研究工作和更新治疗策略，可能会改善诊断方法、治疗介入和预防措施。它强调采取积极主动的方法来对抗沙眼，可能影响医疗保健政策、资金分配以及旨在减轻这种传染性眼病全球负担的国际倡议。

沙眼治疗产业根据药物类别、给药途径、年龄层、配销通路和地区进行分类。

由于其在控制引起疾病的细菌感染方面的既定功效，四环素细分市场将在 2024 年至 2032 年间出现显着的激增。包括阿奇霉素在内的四环素抗生素在治疗和预防沙眼方面发挥关键作用，与全球卫生倡议保持一致。它们的有效性、易于管理和广泛的可用性有助于它们在市场上的主导地位。随着消除沙眼的努力不断加强，四环素领域在提供具有成本效益和可扩展的治疗解决方案方面的作用对于对抗全球范围内这种导致失明的主要传染性原因仍然至关重要。

由于其在分发四环素抗生素等药物方面的可近性和便利性，到 2032 年，零售药局将出现显着的改善。由于这些药物通常用于沙眼的治疗和预防，因此零售药局在确保广泛供应方面发挥着至关重要的作用。他们广泛的网络和以患者为中心的方法有效地满足了对药物解决方案的需求，为全球沙眼的管理和根除工作做出了重大贡献。此细分市场的突出地位凸显了其在促进这种可预防失明原因的基本治疗方法方面的重要作用。

由于高盛行率和广泛的政府倡议，亚太地区沙眼治疗产业份额从 2024 年到 2032 年将实现适度的复合年增长率。该地区积极的医疗保健政策和不断增加的公共卫生基础设施投资有助于有效的疾病管理和治疗的可近性。由于沙眼病例负担沉重，特别是在农村地区，亚太地区作为沙眼治疗市场的适度贡献者，突显了其致力于改善医疗保健结果和减少传染性眼疾影响的承诺。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

AstraZeneca
Bausch Health Companies Inc.
Bayer AG
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

简介目录

Product Code: 9128

Global Trachoma Treatment Market will capture a 5.9% CAGR from 2024 to 2032, fueled by pharmaceutical advancements in treatments like tetracycline and azithromycin, coupled with supportive government initiatives. Improved medications enhance efficacy in combating the bacterial infection that causes trachoma, while government funding and policies bolster access to these treatments. These combined efforts aim to reduce the prevalence of trachoma globally, emphasizing the market's expansion through enhanced treatment accessibility and effectiveness in regions where the disease remains endemic.

For instance, in December 2023, the Royal Society of Tropical Medicine and Hygiene, in collaboration with Sightsavers, released a new research supplement in their journal International Health focusing on updates regarding the infectious eye disease trachoma. This development suggests heightened research efforts and updates on treatment strategies, potentially leading to improved diagnostic methods, therapeutic interventions, and preventive measures. It underscores a proactive approach towards combating trachoma, potentially influencing healthcare policies, funding allocations, and international initiatives aimed at reducing the global burden of this infectious eye disease.

The trachoma treatment industry is classified based on drug class, route of administration, age group, distribution channel, and region.

The tetracycline segment will observe a noteworthy surge between 2024 and 2032, driven by its established efficacy in managing the bacterial infection causing the disease. Tetracycline antibiotics, including azithromycin, are pivotal in treating and preventing trachoma, aligning with global health initiatives. Their effectiveness, ease of administration, and widespread availability contribute to their dominance in the market. As efforts to eliminate trachoma intensify, the tetracycline segment's role in providing cost-effective and scalable treatment solutions remains pivotal in combating this leading infectious cause of blindness worldwide.

The retail pharmacy will encounter a marked upturn through 2032 due to its accessibility and convenience in distributing medications like tetracycline antibiotics. As these medications are often prescribed for trachoma treatment and prevention, retail pharmacies play a crucial role in ensuring widespread availability. Their widespread network and patient-centric approach cater effectively to the demand for pharmaceutical solutions, contributing significantly to the management and eradication efforts against trachoma globally. This segment's prominence underscores its essential role in facilitating easy access to essential treatments for this preventable cause of blindness.

Asia Pacific trachoma treatment industry share will achieve a modest CAGR from 2024 to 2032, attributed to high prevalence rates and extensive government initiatives. The region's proactive healthcare policies and increasing investments in public health infrastructure contribute to effective disease management and treatment accessibility. With a significant burden of trachoma cases, particularly in rural areas, Asia Pacific's role as a modest contributor in the trachoma treatment market underscores its commitment to improving healthcare outcomes and reducing the impact of infectious eye diseases.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High prevalence of trachoma particularly in developing regions
  - 3.2.1.2 Increasing government initiatives and funding
  - 3.2.1.3 Improved access to medicines
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness about trachoma
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Macrolides
5.3 Tetracycline
5.4 Ophthalmic anti-infective
5.5 Sulfonamides

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Topical

Chapter 7 Market Estimates and Forecast, By Age-group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Children
7.3 Adults
7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa